
Impact of House passed legislation on health industries organizations
Summary of the impact of House passed legislation on the pharmaceutical, life sciences, medtech and health services sectors including PwC key observations.
The Trump administration’s implementation of “reciprocal tariffs” continues to be dynamic, prompting a challenging trade landscape for many multinational companies. The President signed an executive order on April 2, made announcements, and released memoranda on this matter. In summary, the new tariffs in place as of the date of this Insight include the following (this list does not reflect all previously existing tariffs):
A wider industry perspective can be found in PwC’s US Tariff Industry Analysis Tax Insight published on April 22 and additional information can be found in the US Customs and Border Protection (CBP) tariff requirements. The administration recently noted that more than 100 countries wish to negotiate trade imbalances with a drive towards an economic level playing field and fair-trading system. As of the date of this Insight, no change in previously noted rates has been announced.
The administration’s trade policies are prompting significant implications for companies operating in or trading with the United States, including companies within the Industrial Products and Manufacturing (IPM) industry. PwC’s Industry Analysis data reflects that the total tariff measures could increase from nearly $23 billion to $268 billion per year (with the implied average tariff rate increasing from 3% to 37% on US imports), although that figure does not take into account countermeasures that trading partners may impose, or behavioral adjustments that companies may make, in reaction to US policy changes.
This Tax Insight serves as an update to our March 17 Industry Analysis, which previously included forecasted reciprocal tariff rates at that time. Note: PwC’s updated Industry Analysis utilizes the tariffs that have been implemented by the United States as of April 15 (based on guidance and specific factors explained in the next section) as well as potential tariffs on so-called Annex II products.
Multinational companies around the world, including companies within the IPM industry, should assess the impact of these trade policies on their global business footprints — with respect to both imports and exports — as well as the potential related opportunities. Close coordination between procurement, supply chain, tax, and other C-suite leaders to formulate short, medium, and long-term strategies is critical, along with data-driven analysis. Advanced tools are available that companies can leverage using their US customs data to quantify the impact — often with unexpected results. This analysis can serve as a powerful foundation to identify “no-regret” actions and to help mitigate risks.
For more details, read the full Tax Insight linked below.
Summary of the impact of House passed legislation on the pharmaceutical, life sciences, medtech and health services sectors including PwC key observations.
The House-passed HR 1 proposes major changes for financial services, including limits on PTE tax, a higher SALT cap, and increasing US tax for certain inbound investors.
House-passed “One Big Beautiful Bill” includes significant information reporting provisions
Washington legislation includes significant tax changes including for B&O tax, sales and use tax, and capital gains tax.